Repeated Dosing Clinical Trial of HL151

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the pharmacokinetic characteristics of bepotastine after multiple oral administration of TALION tab., a IR formulation of bepotastine as reference drug and HL151, a SR formulation of bepotastine as test drug in healthy male adults. Additionally the safety and tolerability of two drugs will be evaluated.

Official Title
-----------------
Repeated Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects

Conditions
-----------------
Rhinitis, Allergic, Perennial

Intervention / Treatment
-----------------
* Drug: HL151
* Drug: TALION tab.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male in the age of 19-45 Body weight ≥ 50kg, BMI 18 29 kg/m2 Subject who sign on an informed consent form willingly Exclusion Criteria: Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease Subject with acute disease within 28 days prior to study medication dosing Subject with known for history of disease which affect on the absorption, distribution, metabolism, excretion of drug Subject with clinically significant chronic disease Positive on the test of HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL Use of any prescription medication within 14 days prior to study medication dosing Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing Subject with clinically significant allergic disease Subject with known for hypersensitivity reaction to bepotastine Subject with any of the following conditions in laboratory test AST/ALT > UNL (upper normal limit) x 2 Total bilirubin > UNL x 2 Renal failure with CLcr < 50mL/min calculated on Cockcroft-Gault [Cockcroft-Gault GFR = (140-age) * (Wt in kg) / (72 *Cr)] SBP<100mmHg or ≥160mmHg, DBP<60mmHg or ≥100mmHg QTc>440msec on ECG Serum potassium < 3.5 mEq/L or > 5.5 mEq/L Immunological incompetence, immune deficiency or taking immunosuppressants Subject who cannot take standard meal Subject with whole blood donation within 60days, component blood donation within 20days prior to study medication dosing Subject with blood transfusion within 30days prior to study medication dosing Participation in any clinical investigation within 90days prior to study medication dosing Continued excessive use of caffeine (caffeine >five cups/day), alcohol(alcohol>30g/day) and severe heavy smoker(cigarette >10 cigarettes per day) Subject with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within 30days prior to study medication dosing Subject who are not using adequate means of contraception Subject with genetic problems such as galactose intolerance, Lapp Lactase Deficiency or glucose-galactose malabsorption Subject with history of drug abuse or drug addiction

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: T-R<br>First period : administration of test drug Second period : administration of reference drug | Drug: HL151<br>* Test drug : HL151. 1T, once a day oral administration, for 4 days<br>Drug: TALION tab.<br>* Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days<br>|
| Experimental: R-T<br>First period : administration of reference drug Second period : administration of test drug | Drug: HL151<br>* Test drug : HL151. 1T, once a day oral administration, for 4 days<br>Drug: TALION tab.<br>* Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the plasma concentration-time curve during a dosing interval(AUCτ,ss) |  | 24 hours after 4 days' repeated dosing | 
| Maximum the plasma concentration during a dosing interval(Cmax,ss) |  | 24 hours after 4 days' repeated dosing | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with adverse events |  | During 4 days' repeated dosing and post-study visit(within 5 days from discharge) |